6.50
Schlusskurs vom Vortag:
$6.63
Offen:
$6.66
24-Stunden-Volumen:
172.16K
Relative Volume:
1.11
Marktkapitalisierung:
$243.34M
Einnahmen:
$128.45M
Nettoeinkommen (Verlust:
$6.54M
KGV:
130.00
EPS:
0.05
Netto-Cashflow:
$-8.79M
1W Leistung:
-6.88%
1M Leistung:
-7.28%
6M Leistung:
+13.74%
1J Leistung:
+44.93%
Lifecore Biomedical Inc Stock (LFCR) Company Profile
Firmenname
Lifecore Biomedical Inc
Sektor
Telefon
(952) 368-4300
Adresse
3515 LYMAN BOULEVARD, CHASKA
Vergleichen Sie LFCR mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
LFCR
Lifecore Biomedical Inc
|
6.50 | 248.40M | 128.45M | 6.54M | -8.79M | 0.05 |
![]()
ZTS
Zoetis Inc
|
141.11 | 63.55B | 9.39B | 2.62B | 2.22B | 5.8121 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
13.71 | 44.47B | 29.96B | 957.25M | 4.77B | 0.2956 |
![]()
HLN
Haleon Plc Adr
|
9.00 | 40.17B | 14.26B | 1.98B | 2.47B | 0.4327 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.03 | 22.99B | 16.70B | -157.13M | 1.19B | -0.1446 |
![]()
UTHR
United Therapeutics Corp
|
440.00 | 20.14B | 3.08B | 1.24B | 1.07B | 25.61 |
Lifecore Biomedical Inc Stock (LFCR) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-09-04 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
2025-05-21 | Eingeleitet | William Blair | Outperform |
2024-09-05 | Eingeleitet | Craig Hallum | Buy |
2024-08-28 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
2023-03-20 | Herabstufung | Stephens | Overweight → Equal-Weight |
Lifecore Biomedical Inc Aktie (LFCR) Neueste Nachrichten
Will Lifecore Biomedical Inc. bounce back from current supportQuarterly Earnings Summary & High Yield Stock Recommendations - newser.com
Chart overlay techniques for tracking Lifecore Biomedical Inc.2025 Geopolitical Influence & Community Verified Trade Signals - newser.com
Is it time to cut losses on Lifecore Biomedical Inc.Watch List & Stepwise Entry and Exit Trade Signals - newser.com
How Lifecore Biomedical Inc. (LDE) stock compares with market leadersTrade Entry Report & Fast Exit and Entry Strategy Plans - newser.com
Analyzing net buyer seller activity in Lifecore Biomedical Inc.2025 Risk Factors & Weekly Hot Stock Watchlists - newser.com
With 45% stake, Lifecore Biomedical, Inc. (NASDAQ:LFCR) seems to have captured hedge funds investors' interest - Yahoo Finance
Rating Downgrade: Lifecore, Ready To Go, But Problems Remain (NASDAQ:LFCR) - Seeking Alpha
CEO Insights: Industry Trends Driving Strong Tailwinds for U.S.-based CDMOs - Contract Pharma
Using fundamentals and technicals on Lifecore Biomedical Inc.Swing Trade & Weekly Watchlist for Hot Stocks - newser.com
Why pension funds invest in Lifecore Biomedical Inc. (LDE) stockMarket Growth Report & Reliable Price Breakout Alerts - newser.com
Real time alert setup for Lifecore Biomedical Inc. performanceQuarterly Earnings Summary & Community Consensus Stock Picks - newser.com
Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Published on: 2025-10-05 05:34:33 - newser.com
Lifecore granted Sector Weight rating at KeyBanc on growth trajectory - MSN
Can volume confirm reversal in Lifecore Biomedical Inc.Market Trend Report & AI Driven Price Forecasts - newser.com
Is Lifecore Biomedical Inc. (LDE) stock suitable for passive index funds2025 Growth vs Value & Fast Exit and Entry Strategy Plans - newser.com
Quantitative breakdown of Lifecore Biomedical Inc. recent moveOil Prices & Real-Time Stock Entry Alerts - newser.com
LIFECORE SHAREHOLDER ALERT: Kaskela Law LLC Announces - GlobeNewswire
What drives Lifecore Biomedical Inc stock priceStock Buy Signals & Big Returns, Small Investment – Learn How - earlytimes.in
Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Lifecore Biomedical Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView
What analysts say about Lifecore Biomedical Inc LDE stockStraddle and Strangle Trades & Free Stock Education Platform for New Investors - earlytimes.in
What analysts say about Lifecore Biomedical Inc stockMarket Correction Analysis & High Profit Market Growth - earlytimes.in
Is Lifecore Biomedical Inc a good long term investmentTechnical Analysis Insights & Learn to Trade with Real-Time Feedback - earlytimes.in
Will Lifecore Biomedical Inc. (LDE) stock deliver compounding returnsMarket Rally & Weekly Market Pulse Updates - newser.com
What drives Lifecore Biomedical Inc LDE stock priceEx-Dividend Date Alerts & Small Budget Trading Plans - earlytimes.in
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
LIFECORE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
Published on: 2025-09-27 16:31:16 - newser.com
Finanzdaten der Lifecore Biomedical Inc-Aktie (LFCR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Lifecore Biomedical Inc-Aktie (LFCR) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
English Aron R. | 10% Owner |
May 28 '25 |
Sale |
7.12 |
150,419 |
1,071,555 |
264,180 |
English Aron R. | 10% Owner |
May 23 '25 |
Sale |
6.75 |
96,137 |
649,386 |
1,554,103 |
English Aron R. | 10% Owner |
May 13 '25 |
Sale |
7.00 |
12,334 |
86,353 |
1,650,240 |
English Aron R. | 10% Owner |
May 12 '25 |
Sale |
7.03 |
45,698 |
321,426 |
1,662,574 |
English Aron R. | 10% Owner |
May 08 '25 |
Sale |
7.00 |
5,098 |
35,693 |
1,708,972 |
English Aron R. | 10% Owner |
May 09 '25 |
Sale |
7.00 |
700 |
4,900 |
1,708,272 |
English Aron R. | 10% Owner |
May 05 '25 |
Sale |
7.08 |
24,543 |
173,831 |
1,730,618 |
English Aron R. | 10% Owner |
May 07 '25 |
Sale |
7.01 |
15,847 |
111,099 |
1,714,070 |
English Aron R. | 10% Owner |
May 06 '25 |
Sale |
7.05 |
701 |
4,940 |
1,729,917 |
Josephs Paul | Chief Executive Officer |
Jan 08 '25 |
Buy |
5.74 |
17,000 |
97,580 |
559,717 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):